scholarly journals Wearable cardioverter defibrillator for peripartum cardiomyopathy patients

2015 ◽  
Vol 17 (2) ◽  
pp. 234-234 ◽  
Author(s):  
James D. Frett
Keyword(s):  
Peripartum Cardiomyopathy ◽  
Cardioverter Defibrillator ◽  
Wearable Cardioverter Defibrillator

scholarly journals A Tragic Case of Wearable Cardioverter-Defibrillator Failure

2021 ◽  
Vol 3 (2) ◽  
pp. 322-326
Author(s):  
Ariel Vinas ◽  
Debanshu Roy ◽  
Cynthia Saunders ◽  
Auroa Badin ◽  
Manoj M. Panday ◽  
...  
Keyword(s):  
Cardioverter Defibrillator ◽  
Wearable Cardioverter Defibrillator

scholarly journals The Wearable Cardioverter/ Defibrillator: retrospective analysis of efficacy, safety and adherence

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
J Ehmsen ◽  
H Keller ◽  
C Stoellberger
Keyword(s):  
Systolic Function ◽  
Detection Algorithm ◽  
Shock Rate ◽  
Information Network ◽  
Independent Data ◽  
Icd Implantation ◽  
Cardioverter Defibrillator ◽  
Wearable Cardioverter Defibrillator ◽  
Inappropriate Shocks ◽  
High Adherence

Abstract Background The use of the Wearable Cardioverter Defibrillator (WCD) is recommended in national, European and American guidelines. However, there are almost exclusively data from the manufacturer's own data network. Independent data on the experience with the WCD are rare. Objective The aim of the retrospective study from one cardiologic department was to record efficiency, safety and compliance of the WCD. Patients and methods The study included all patients, to whom a WCD was described between 1.11.2010 and 1.5.2018 at one cardiologic department. Clinical data were obtained from the patients' records and the data about the WCD from the information network of the manufacturer. Results This study enrolled 66 patients, 51 males (77%) and 15 females (23%). The median age was 55 years (IQR: 45–63). They suffered from ischemic cardiomyopathy (n=33; 49%), dilated cardiomyopathy (n=12; 18%), myocarditis (n=7; 11%), explantation of an implantable cardioverter/defibrillator (ICD; n=5; 8%) and other indications (n=6; 9%). The median wearing time of the WCD was 73 days (interquartile range-IQR: 39–126), with median daily use of 22.91 h (IQR: 19.58–23.61). Among 38 patients with LVEF ≤35%, LVEF improved to ≥35% in 19 patients (50%) during WCD therapy. Over 1600 times the WCD detected a VT falsely. Four patients (8%) suffered from 212 non-sustained VT. One patient was successfully shocked because of ventricular fibrillation (appropriate shock rate: 1.5%). There were no inappropriate shocks. All patients, who wore the WCD, survived and one patient died when he did not wear the WCD. At the end of therapy 32 patients (48%) received an ICD. In terms of wearing time and events (shocks, arrhythmias, artifacts) there were no significant differences between patients receiving ICD and those who did not receive an ICD. Patients who received an ICD had a significantly lower LVEF after 3 months than patients who did not receive an ICD. Conclusion Our data confirm, that the WCD is safe and that the patients, who wear a WCD, have a high adherence. More than half of the patients with reduced LVEF improved their systolic function during WCD therapy, thus obviating the need for ICD implantation. Questions about the effectiveness of the detection algorithm remained open. Funding Acknowledgement Type of funding source: None

Abstract 18973: Left Ventricular Function Improvement After Recent MI in Patients Using a Wearable Cardioverter Defibrillator

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Chingping Wan ◽  
Steven J Szymkiewicz
Keyword(s):  
Heart Failure ◽  
Left Ventricular Function ◽  
Ventricular Function ◽  
Clinical Characteristics ◽  
Treated Group ◽  
Left Ventricular ◽  
Icd Implantation ◽  
Cardioverter Defibrillator ◽  
Wearable Cardioverter Defibrillator

Introduction: The wearable cardioverter defibrillator (WCD) has been used to protect AMI patients with reduced LVEF (≤35%) until ICD evaluation is recommended. The rate of EF improvement (e.g. EF>35%) over the initial 8-12 weeks after AMI has not been reported. METHODS: The manufacturer-maintained registry was searched for AMI patients who received a WCD shock for VT/VF between 05/2008 and 02/2013. The treated group was matched (1: ~4) with event-free WCD patients by ICD-9 code (410.*), gender, age and prescription date. Chart notes were reviewed for clinical characteristics. Follow-up was assessed through the registry and Social Security Death Master File. RESULTS: There were 992 (age=63±12, female=20.2%) AMI patients included in the final analysis, 206 treated by WCD and 786 event-free patients. Median follow-up was 334 days. Mean length of WCD use was 67±506 (median=38) days. Subgroup clinical characteristics are presented in Table 1. In the event-free group, 289 (38.9%) patients showed EF improvement to >35%. Nine (4.5%) in the treated group continued wearing the WCD until EF recovery, while 125 (60.7%) received ICD. Absence of recorded heart failure and/or diabetes were associated with LVEF recovery (p<.0001). CONCLUSION: In our study, almost 40% of AMI patients with initial EF ≤35% had EF improvement in two months. The EF recovery group had lower rates of heart failure and diabetes. WCD allows time for left ventricular function recovery in low EF post MI patients, optimizing ICD implantation decisions.

scholarly journals Wearable cardioverter defibrillator for foreigners, a Tajikistani woman with ventricular fibrillation: a case report

2019 ◽  
Vol 26 (5) ◽  
pp. 385-390
Author(s):  
Kenzo Ichimura ◽  
Masaaki Nishihara ◽  
Yasushi Mukai ◽  
Toyokazu Uwatoku ◽  
Kentaro Tokuda ◽  
...  
Keyword(s):  
Case Report ◽  
Ventricular Fibrillation ◽  
Cardioverter Defibrillator ◽  
Wearable Cardioverter Defibrillator
Sign in / Sign up

Export Citation Format

Share Document